Patterns of Acute Intracranial Hemorrhage in Adult Patients with Bilateral and Unilateral Moyamoya Disease

Author(s): Zhiyuan Yu, Jun Zheng, Rui Guo, Hao Li, Chao You, Lu Ma*.

Journal Name: Current Neurovascular Research

Volume 16 , Issue 3 , 2019

Become EABM
Become Reviewer

Abstract:

Background: Moyamoya disease (MMD) is a rare cerebrovascular disease. The difference of hemorrhagic patterns in adult patients with bilateral and unilateral MMD is still unclear.

Objective: For a better understanding of their characteristics, we compared the patterns of acute intracranial hemorrhage in adult patients with bilateral and unilateral MMD.

Methods: Adult MMD patients with acute intracranial hemorrhage were retrospectively included. Clinical and radiological characteristics of adult patients with bilateral and unilateral MMD were collected and analyzed. Chi-square test, t-test, or rank sum test were used for statistical analyses.

Results: A total of 107 patients were included. Among 74 patients with bilateral MMD, 9 (12.2%) were at Suzuki Stage 2, 48 (64.9%) were at Stage 3, 16 (21.6%) were at Stage 4, and another (1.4%) was at Stage 5. However, in patients with unilateral MMD, 8 (24.2%) were at Stage 2, 23 (69.7%) were at Stage 3, and 2 (6.1%) were at Stage 4. Intraparenchymal hemorrhage was found in 40 (54.1%) patients with bilateral MMD and 16 (48.5%) patients with unilateral MMD (P=0.594). Intraventricular hemorrhage was shown in 65 (87.8%) patients with bilateral MMD and 19 (57.6%) patients with unilateral MMD (P<0.001). Subarachnoid hemorrhage was observed in 17 (23.0%) patients with bilateral MMD and 18 (54.5%) patients with unilateral MMD (P=0.001).

Conclusion: Unilateral MMD patients with acute intracranial hemorrhage are at the earlier Suzuki stage than the bilateral MMD patients. Intraventricular hemorrhage occurs more frequently in bilateral MMD, while subarachnoid hemorrhage is more frequent in unilateral MMD.

Keywords: Intracranial hemorrhage, intraparenchymal hemorrhage, intraventricular hemorrhage, moyamoya disease, subarachnoid hemorrhage, suzuki stage.

[1]
Fujimura M, Bang OY, Kim JS. Moyamoya disease. Front Neurol Neurosci 2016; 40: 204-20.
[2]
Hayashi K, Horie N, Suyama K, Nagata I. An epidemiological survey of Moyamoya disease, unilateral Moyamoya disease and quasi-Moyamoya disease in Japan. Clin Neurol Neurosurg 2013; 115(7): 930-3.
[3]
Scott RM, Smith ER. Moyamoya disease and Moyamoya syndrome. N Engl J Med 2009; 360(12): 1226-37.
[4]
Kim JS. Moyamoya disease: Epidemiology, clinical features, and diagnosis. J Stroke 2016; 18(1): 2-11.
[5]
Chen PC, Yang SH, Chien KL, Tsai IJ, Kuo MF. Epidemiology of Moyamoya disease in Taiwan: A nationwide population-based study. Stroke 2014; 45(5): 1258-63.
[6]
Kim T, Lee H, Bang JS, Kwon OK, Hwang G, Oh CW. Epidemiology of Moyamoya disease in Korea: Based on National Health Insurance Service Data. J Korean Neurosurg Soc 2015; 57(6): 390-5.
[7]
Kainth D, Chaudhry SA, Kainth H, Suri FK, Qureshi AI. Epidemiological and clinical features of Moyamoya disease in the USA. Neuroepidemiology 2013; 40(4): 282-7.
[8]
Fujimura M, Tominaga T. Diagnosis of Moyamoya disease: International standard and regional differences. Neurol Med Chir (Tokyo) 2015; 55(3): 189-93.
[9]
Hayashi K, Horie N, Izumo T, Nagata I. A nationwide survey on unilateral Moyamoya disease in Japan. Clin Neurol Neurosurg 2014; 124: 1-5.
[10]
Kelly ME, Bell-Stephens TE, Marks MP, Do HM, Steinberg GK. Progression of unilateral Moyamoya disease: A clinical series. Cerebrovasc Dis 2006; 22(2-3): 109-15.
[11]
Zhang Q, Wang R, Liu Y, et al. Clinical features and long-term outcomes of unilateral Moyamoya disease. World Neurosurg 2016; 96: 474-82.
[12]
Chen JB, Liu Y, Zhou LX, Sun H, He M, You C. Increased prevalence of autoimmune disease in patients with unilateral compared with bilateral Moyamoya disease. J Neurosurg 2016; 124(5): 1215-20.
[13]
Wan M, Duan L. Recent progress in hemorrhagic Moyamoya disease. Br J Neurosurg 2015; 29(2): 189-91.
[14]
Liu P, Han C, Li DS, Lv XL, Li YX, Duan L. Hemorrhagic Moyamoya disease in children: Clinical, angiographic features, and long-term surgical outcome. Stroke 2016; 47(1): 240-3.
[15]
Ge P, Zhang Q, Ye X, et al. Clinical features of hemorrhagic Moyamoya disease in China. World Neurosurg 2017; 106: 224-30.
[16]
Li Q, Qu L, Yuan Y, et al. Analysis of the clinical characteristics of hemorrhagic Moyamoya disease in the Jilin province of northeastern China: A single-center study of 212 cases. Biomed Rep 2018; 8(2): 191-7.
[17]
Jiang H, Ni W, Xu B, et al. Outcome in adult patients with hemorrhagic Moyamoya disease after combined extracranial-intracranial bypass. J Neurosurg 2014; 121(5): 1048-55.
[18]
Hamada J, Hashimoto N, Tsukahara T. Moyamoya disease with repeated intraventricular hemorrhage due to aneurysm rupture. Report of two cases. J Neurosurg 1994; 80(2): 328-31.
[19]
Jang DK, Lee KS, Rha HK, et al. Clinical and angiographic features and stroke types in adult Moyamoya disease. AJNR Am J Neuroradiol 2014; 35(6): 1124-31.
[20]
Wan M, Han C, Xian P, Yang WZ, Li DS, Duan L. Moyamoya disease presenting with subarachnoid hemorrhage: Clinical features and neuroimaging of a case series. Br J Neurosurg 2015; 29(6): 804-10.
[21]
Saeki N, Nakazaki S, Kubota M, et al. Hemorrhagic type Moyamoya disease. Clin Neurol Neurosurg 1997; 99(Suppl. 2): S196-201.
[22]
Veselinovic N, Zidverc-Trajkovic J, Semnic R, Tomic G, Sternic N, Bjelan M. Moyamoya, unilateral to bilateral in one year. Vasa 2014; 43(4): 284-6.
[23]
Houkin K, Abe H, Yoshimoto T, Takahashi A. Is “unilateral” Moyamoya disease different from Moyamoya disease? J Neurosurg 1996; 85(5): 772-6.
[24]
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with Canakinumab for Atherosclerotic disease. N Engl J Med 2017; 377(12): 1119-31.
[25]
Funaki T, Fushimi Y, Takahashi JC, et al. Visualization of periventricular collaterals in Moyamoya disease with flow-sensitive black-blood magnetic resonance angiography: Preliminary experience. Neurol Med Chir (Tokyo) 2015; 55(3): 204-9.
[26]
Abhinav K, Furtado SV, Nielsen TH, et al. Functional outcomes after revascularization procedures in patients with hemorrhagic moyamoya disease. Neurosurgery 2019. [EPub ahead of Print].
[27]
Li Q, Gao Y, Xin W, et al. Meta-analysis of the prognosis of different treatments of symptomatic moyamoya disease. World Neurosurg 2019. [EPub ahead of Print].
[28]
Nomura S, Yamaguchi K, Akagawa H, et al. Genotype-phenotype correlation in long-term cohort of Japanese patients with moyamoya disease Cerebrovascular diseases (Basel, Switzerland) 2019. [EPub ahead of Print].


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 3
Year: 2019
Page: [202 - 207]
Pages: 6
DOI: 10.2174/1567202616666190621093652
Price: $58

Article Metrics

PDF: 34
HTML: 2